{
    "organizations": [],
    "uuid": "7a7e6d9592b7696dc3b8e3225ae43b26cc80d768",
    "author": "",
    "url": "https://www.reuters.com/article/brief-viela-bio-spins-out-of-medimmune-r/brief-viela-bio-spins-out-of-medimmune-raises-up-to-250-million-in-series-a-financing-idUSASB0C7XJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Viela Bio Spins Out Of Medimmune Raises Up To $250 Million In Series A Financing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "  in 19 minutes BRIEF-Viela Bio Spins Out Of Medimmune Raises Up To $250 Million In Series A Financing Reuters Staff 1 Min Read Feb 28 (Reuters) - Astrazeneca Plc: * VIELA BIO SPINS OUT OF MEDIMMUNE; RAISES UP TO $250 MILLION IN SERIES A FINANCING, 6 DIMENSIONS CAPITAL LEADS INVESTMENT * VIELA BIO ​- ‍ SERIES A ROUND CO-LED BY 6 DIMENSIONS CAPITAL, BOYU CAPITAL, HILLHOUSE CAPITAL, WITH PARTICIPATION FROM TEMASEK AND SIRONA CAPITAL * VIELA BIO SAYS ‍ASTRAZENECA WILL REMAIN LARGEST MINORITY SHAREHOLDER OF VIELA BIO * VIELA BIO SAYS ‍MEDIMMUNE TO CONTRIBUTE THREE CLINICAL, THREE PRECLINICAL POTENTIAL NEW MEDICINES TO CO, INCLUDING INEBILIZUMAB  ",
    "published": "2018-02-28T12:38:00.000+02:00",
    "crawled": "2018-02-28T13:02:21.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "bio",
        "spin",
        "medimmune",
        "raise",
        "million",
        "series",
        "financing",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "astrazeneca",
        "plc",
        "viela",
        "bio",
        "spin",
        "medimmune",
        "raise",
        "million",
        "series",
        "financing",
        "dimension",
        "capital",
        "lead",
        "investment",
        "viela",
        "bio",
        "series",
        "round",
        "dimension",
        "capital",
        "boyu",
        "capital",
        "hillhouse",
        "capital",
        "participation",
        "temasek",
        "sirona",
        "capital",
        "viela",
        "bio",
        "say",
        "remain",
        "largest",
        "minority",
        "shareholder",
        "viela",
        "bio",
        "viela",
        "bio",
        "say",
        "contribute",
        "three",
        "clinical",
        "three",
        "preclinical",
        "potential",
        "new",
        "medicine",
        "co",
        "including",
        "inebilizumab"
    ]
}